| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Atish Patel, Travis L Calkins, Justin D Vidal, Pragati S Coder, Scott Carrier, Giri Gokulrangan, Ananth Srinivas R Chakilam, Sandeep sAkare, Richard J Briscoe, Madhu S Monda. Effects of Dopamine Agonists on the Estradiol-Induced Prolactin Surge in Ovariectomized Female Wistar Han Rats. Toxicological sciences : an official journal of the Society of Toxicology. 2025-03-12. PMID:40070087. |
dopamine agonists (das) are approved for the treatment of hypodopaminergic pathologies, including parkinson's disease, restless legs syndrome, and periodic limb movement disorder. |
2025-03-12 |
2025-03-14 |
human |
| Maximilian Scheifele, Johannes Gnörich, Elisabeth Schröder, Sophie C Kunte, Zachary Ells, Johannes Hagen, Sabrina Katzdobler, Carla Palleis, Alexander Bernhardt, Alexander Jäck, Nicolai Franzmeier, Maximilian Fischer, Johannes Levin, Günter U Höglinger, Rudolf A Werner, Matthias Brende. Feasibility of a single-day protocol for SPECT and PET assessment of dopamine transporter availability, cardiac innervation and metabolic patterns in patients with movement disorders. European journal of nuclear medicine and molecular imaging. 2025-03-11. PMID:40064709. |
feasibility of a single-day protocol for spect and pet assessment of dopamine transporter availability, cardiac innervation and metabolic patterns in patients with movement disorders. |
2025-03-11 |
2025-03-13 |
Not clear |
| Jakub Kasprzak, Jarosław Dulski, Filip Przytuła, Dariusz Koziorowski, Magdalena Kwaśniak-Butowska, Witold Sołtan, Anna Roszmann, Katarzyna Śmiłowska, Michał Schinwelski, Jarosław Sławe. Levodopa and dopamine agonist phobia in Parkinson's Disease: - does it really matter? A survey on treatment patterns in Polish tertiary centres. Neurologia i neurochirurgia polska. 2025-02-26. PMID:40007330. |
to investigate the treatment strategies of parkinson's disease (pd) among movement disorder specialists in tertiary centres in poland, and how literature warnings (levodopa and dopamine agonist phobia) have influenced their practice. |
2025-02-26 |
2025-02-28 |
Not clear |
| Maibam Pooya Chanu, Gajendra Kumar, Ramana Kumar Vinjamuri, Nayan M Kakot. Computational model for control of hand movement in Parkinson's disease using deep brain stimulation. Experimental brain research. vol 243. issue 3. 2025-02-23. PMID:39987542. |
parkinson's disease (pd) is a progressive neurological disorder characterized by the loss of dopamine in the substantia nigra resulting in movement disorder. |
2025-02-23 |
2025-02-26 |
human |
| Hua Bai, Huan Gu, Wenhui Zhou, Guolin Shi, Jinyuan Yan, Yanmei Su, Wenhu Li, Yixin Li, Chidi Zhong, Ninghui Zhao, Xiaowei Huan. PD-like pathogenesis induced by intestinal exposure to microplastics: An in vivo study of animal models to a public health survey. Journal of hazardous materials. vol 486. 2025-01-03. PMID:39752824. |
we found that low-dose microplastic exposure accelerated dopamine neuron degeneration and the onset of movement disorders in vivo, inducing a pd-like neuronal pathology through its effects on the intestinal mucosal barrier, immune barrier, and microbial barrier. |
2025-01-03 |
2025-01-06 |
mouse |
| José L Lanciego, José A Obes. Functional Neuroanatomy of the Normal and Pathological Basal Ganglia. Cold Spring Harbor perspectives in medicine. 2024-12-18. PMID:39694693. |
dopamine released from the substantia nigra is the underlying driving force keeping the basal ganglia network under proper equilibrium and, indeed, reduction of dopamine levels triggers basal ganglia dysfunction, setting the groundwork for several movement disorders. |
2024-12-18 |
2024-12-21 |
Not clear |
| Taro Okunomiya, Dai Watanabe, Haruhiko Banno, Takayuki Kondo, Keiko Imamura, Ryosuke Takahashi, Haruhisa Inou. Striosome circuitry stimulation inhibits striatal dopamine release and locomotion. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2024-12-02. PMID:39622644. |
these compartmentalized structures have distinct roles in the development of movement disorders, although the functional significance of the striosome compartment for motor control and dopamine regulation remains to be elucidated. |
2024-12-02 |
2024-12-06 |
mouse |
| Yini Liao, Brian S Muntea. KCTD1 regulation of Adenylyl cyclase type 5 adjusts striatal cAMP signaling. Proceedings of the National Academy of Sciences of the United States of America. vol 121. issue 43. 2024-10-16. PMID:39413138. |
dopamine transfers information to striatal neurons, and disrupted neurotransmission leads to motor deficits observed in movement disorders. |
2024-10-16 |
2024-10-19 |
mouse |
| Huifang Wu, Minghao Yan, Tong Wu, Xiaodong Ha. MC-LR disrupts dopamine synthesis in the substantia nigra of midbrain by enhancing the chaperone-mediated autophagy pathway through direct binding to ERK2. Journal of hazardous materials. vol 480. 2024-10-16. PMID:39413523. |
the reduction in dopamine levels is a key factor contributing to movement disorders in humans with pd. |
2024-10-16 |
2024-10-19 |
mouse |
| Jinming Liu, Zhongqing Ji, Qisheng He, Huanhuan Chen, Xiaojing Xu, Qiuhao Mei, Ya'nan Hu, Huanxiang Zhan. Direct conversion of human umbilical cord mesenchymal stem cells into dopaminergic neurons for Parkinson's disease treatment. Neurobiology of disease. 2024-09-29. PMID:39343249. |
furthermore, cins treatment significantly increased the number of tyrosine hydroxylase-positive cells and the concentration of dopamine in the striatum, effectively ameliorating movement disorders in pd mice. |
2024-09-29 |
2024-10-02 |
mouse |
| Ranran Lu, Xu Zhou, Lijie Zhang, Mengdie Hao, Xinling Yan. Nrf2 Deficiency Exacerbates Parkinson's Disease by Aggravating NLRP3 Inflammasome Activation in MPTP-Induced Mouse Models and LPS-Induced BV2 Cells. Journal of inflammation research. vol 17. 2024-09-16. PMID:39281779. |
parkinson's disease (pd) is a movement disorder characterized by the progressive loss of dopamine neurons. |
2024-09-16 |
2024-09-19 |
mouse |
| Ahmed Bouhouche, Leila Tamaoui, Nazha Birou. The Pan African medical journal. vol 47. 2024-07-08. PMID:38974698. |
dopa-responsive dystonia (drd) is a hereditary movement disorder due to a selective nigrostriatal dopamine deficiency. |
2024-07-08 |
2024-07-11 |
Not clear |
| Hannah Holden, Shruti Venkatesh, Carla Budrow, Sareen Nezaria, Michael Coyle, Ashley Centner, Natalie Lipari, Grace McManus, Christopher Bisho. The effects of L-DOPA on gait abnormalities in a unilateral 6-OHDA rat model of Parkinson's disease. Physiology & behavior. vol 281. 2024-05-25. PMID:38723388. |
parkinson's disease (pd) is a neurodegenerative movement disorder characterized by dopamine (da) cell loss in the substantia nigra pars compacta (snc). |
2024-05-25 |
2024-05-27 |
rat |
| Ratna Dini Haryuni, Takamasa Nukui, Jin-Lan Piao, Takashi Shirakura, Chieko Matsui, Tomoyuki Sugimoto, Kousuke Baba, Shunya Nakane, Yuji Nakatsuj. Elevated Serum Xanthine Oxidase and Its Correlation with Antioxidant Status in Patients with Parkinson's Disease. Biomolecules. vol 14. issue 4. 2024-04-27. PMID:38672506. |
parkinson's disease (pd) is a neurodegenerative movement disorder associated with a loss of dopamine neurons in the substantia nigra. |
2024-04-27 |
2024-04-29 |
Not clear |
| Jerzy K Kulski, Shingo Suzuki, Takashi Shiina, Abigail L Pfaff, Sulev Kõk. Regulatory SVA retrotransposons and classical HLA genotyped-transcripts associated with Parkinson's disease. Frontiers in immunology. vol 15. 2024-04-09. PMID:38590523. |
parkinson's disease (pd) is a neurodegenerative and polygenic disorder characterised by the progressive loss of neural dopamine and onset of movement disorders. |
2024-04-09 |
2024-04-11 |
human |
| Roongroj Bhidayasiri, Onanong Phokaewvarangkul, Hui-Fang Shang, Thien Thien Lim, Jin Whan Cho, Pramod Kumar Pal, Hirohisa Watanab. Tardive dyskinesia in Asia- current clinical practice and the role of neurologists in the care pathway. Frontiers in neurology. vol 15. 2024-02-29. PMID:38419696. |
tardive dyskinesia (td) is a movement disorder that can arise as a side effect of treatment with dopamine receptor-blocking agents (drbas), including antipsychotic drugs (apds) used to manage psychotic illnesses. |
2024-02-29 |
2024-03-02 |
Not clear |
| Suzita Mohd Noor, Chee Ern David Wong, Pooi-Fong Wong, Anwar Norazi. Generation of glial cell-derived neurotrophic factor (gdnf) morphants in zebrafish larvae by cerebroventricular microinjection of vivo morpholino. Methods in cell biology. vol 181. 2024-02-01. PMID:38302238. |
deficiency of dopamine due to advanced age and accumulative dopaminergic neuron defects can lead to movement disorders such as parkinson's disease. |
2024-02-01 |
2024-02-04 |
human |
| Louisa A Christie, Nicola L Brice, Anna Rowland, Louise Dickson, Rishi Anand, Martin Teall, Kevin J Doyle, Lakshminarayana Narayana, Christine Mitchell, Jenna R M Harvey, Victoria Mulligan, Lee A Dawson, Stephanie J Cragg, Mark Carlton, Roland W Bürl. Discovery of Journal of medicinal chemistry. 2023-08-31. PMID:37651656. |
this subunit modulates dopamine neurotransmission and may have therapeutic potential in movement disorders. |
2023-08-31 |
2023-09-07 |
Not clear |
| Gabriella Tandra, Amy Yoone, Rhea Mathew, Minzhi Wang, Chadwick M Hales, Cassie S Mitchel. Literature-Based Discovery Predicts Antihistamines Are a Promising Repurposed Adjuvant Therapy for Parkinson's Disease. International journal of molecular sciences. vol 24. issue 15. 2023-08-12. PMID:37569714. |
parkinson's disease (pd) is a movement disorder caused by a dopamine deficit in the brain. |
2023-08-12 |
2023-08-16 |
Not clear |
| Leslie Citrome, Jonathan M Meye. Reviewing Non-Dopaminergic Mechanisms for Positive and Negative Schizophrenia Symptom Management. The Journal of clinical psychiatry. vol 84. issue 4. 2023-08-09. PMID:37555680. |
for decades, treatment for schizophrenia has focused on antipsychotics (aps) that reduce excess dopamine signaling to the associative striatum, which also blocks dopamine signaling in the dorsal striatum, creating movement disorders. |
2023-08-09 |
2023-08-16 |
Not clear |